- 07/26/2018
- EISAI AND BIOGEN ANNOUNCE DETAILED RESULTS OF PHASE II CLINICAL STUDY OF BAN2401 IN EARLY ALZHEIMER’S DISEASE AT ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2018
- 07/26/2018
- EISAI AND BIOGEN PRESENT DETAILED RESULTS FROM PHASE II CLINICAL STUDY OF ELENBECESTAT IN MCI AND MILD TO MODERATE ALZHEIMER’S DISEASE AT ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2018
- 07/19/2018
- LATEST DATA ON EISAI’S ALZHEIMER’S DISEASE / DEMENTIA PIPELINE TO BE PRESENTED AT ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2018
- 06/21/2018
- AbbVie and Eisai Announce the Launch of HUMIRA® for Subcutaneous Injection 20 mg Syringe 0.2 mL, A New Pediatric Formulation of HUMIRA®
- 06/04/2018
- EISAI AND MERCK & CO., INC., KENILWORTH, N.J., U.S.A. ANNOUNCE DATA AT 2018 ASCO ANNUAL MEETING FROM INVESTIGATIONAL STUDIES OF LENVIMA® AND KEYTRUDA® COMBINATION THERAPY IN FOUR DIFFERENT TUMOR TYPES
- 05/31/2018
- U.S. FDA DESIGNATES FOR PRIORITY REVIEW EISAI’S SUPPLEMENTAL NEW DRUG APPLICATION FOR ANTIEPILEPTIC DRUG FYCOMPA® AS TREATMENT FOR PEDIATRIC PATIENTS WITH EPILEPSY
- 05/29/2018
- Eisai China Won the “Best HR Teams in Greater China” of HRoot Awards 2018
- 04/26/2018
- The Eisai China Scholarships Program Supports China’s Education for 18 Consecutive Years
- 04/20/2018
- EISAI TO PRESENT LATEST DATA ON PERAMPANEL AND RUFINAMIDE AT ANNUAL AMERICAN ACADEMY OF NEUROLOGY MEETING
- 04/19/2018
- World’s First Bile Acid Transporter Inhibitor “GOOFICE® 5mg Tablet” Launched in Japan
